Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software
Fresenius Medical Care (FMS) has reached a milestone of over 14,000 U.S. patients using its NxStage systems for Home Hemodialysis (HHD). The company has also launched the NxStage® Versi®HD with GuideMe Software, a new home dialysis machine designed to simplify treatment and improve user experience. Between January and April 2024, new HHD patients starting treatment with NxStage in the U.S. grew by 18% compared to the same period in 2023. The Versi®HD with GuideMe Software, FDA-cleared in 2023, has gained significant interest from various dialysis providers. Its advanced technology aims to enhance ease of use, improve training time, and accommodate diverse learning styles.
Fresenius Medical Care (FMS) ha raggiunto un traguardo di oltre 14.000 pazienti statunitensi che utilizzano i suoi sistemi NxStage per l'emodialisi domiciliare (HHD). L'azienda ha anche lanciato il NxStage® Versi®HD con GuideMe Software, una nuova macchina per la dialisi domiciliare progettata per semplificare il trattamento e migliorare l'esperienza dell'utente. Tra gennaio e aprile 2024, il numero di nuovi pazienti HHD che iniziano il trattamento con NxStage negli Stati Uniti è aumentato del 18% rispetto allo stesso periodo del 2023. Il Versi®HD con GuideMe Software, autorizzato dalla FDA nel 2023, ha suscitato un notevole interesse da parte di vari fornitori di dialisi. La sua tecnologia avanzata mira a migliorare la facilità d'uso, ridurre i tempi di formazione e adattarsi a diversi stili di apprendimento.
Fresenius Medical Care (FMS) ha llegado a un hito de más de 14,000 pacientes en los Estados Unidos utilizando sus sistemas NxStage para Hemodiálisis Domiciliaria (HHD). La compañía también ha lanzado el NxStage® Versi®HD con GuideMe Software, una nueva máquina de diálisis hogareña diseñada para simplificar el tratamiento y mejorar la experiencia del usuario. Entre enero y abril de 2024, el número de nuevos pacientes de HHD que comienzan tratamiento con NxStage en los EE. UU. creció un 18% en comparación con el mismo período de 2023. El Versi®HD con GuideMe Software, aprobado por la FDA en 2023, ha atraído un interés significativo de varios proveedores de diálisis. Su tecnología avanzada tiene como objetivo mejorar la facilidad de uso, reducir el tiempo de capacitación y adaptarse a diversos estilos de aprendizaje.
프레제니우스 메디컬 케어(FMS)는 14,000명이 넘는 미국 환자가 홈 혈액 투석(HHD)을 위한 NxStage 시스템을 사용하고 있는 이정표를 달성했습니다. 이 회사는 또한 치료를 간소화하고 사용자 경험을 개선하도록 설계된 새로운 가정용 투석기인 NxStage® Versi®HD with GuideMe Software를 출시했습니다. 2024년 1월부터 4월 사이에 미국에서 NxStage로 치료를 시작하는 새로운 HHD 환자가 2023년 같은 기간에 비해 18% 증가했습니다. 2023년에 FDA 승인을 받은 Versi®HD with GuideMe Software는 다양한 투석 공급자로부터 많은 관심을 받고 있습니다. 이 고급 기술은 사용 편의성을 향상시키고 교육 시간을 개선하며 다양한 학습 스타일에 적응하는 것을 목표로 합니다.
Fresenius Medical Care (FMS) a atteint une étape importante avec plus de 14 000 patients américains utilisant ses systèmes NxStage pour l'hémodialyse à domicile (HHD). La société a également lancé le NxStage® Versi®HD avec GuideMe Software, une nouvelle machine de dialyse à domicile conçue pour simplifier le traitement et améliorer l'expérience utilisateur. Entre janvier et avril 2024, le nombre de nouveaux patients HHD commençant un traitement avec NxStage aux États-Unis a augmenté de 18% par rapport à la même période en 2023. Le Versi®HD avec GuideMe Software, approuvé par la FDA en 2023, a suscité un intérêt significatif de la part de divers fournisseurs de dialyse. Sa technologie avancée vise à améliorer la facilité d'utilisation, à raccourcir le temps de formation et à s'adapter à divers styles d'apprentissage.
Fresenius Medical Care (FMS) hat einen Meilenstein von über 14.000 US-Patienten erreicht, die seine NxStage-Systeme für die häusliche Hämodialyse (HHD) nutzen. Das Unternehmen hat auch die NxStage® Versi®HD mit GuideMe Software eingeführt, eine neue häusliche Dialysemaschine, die entwickelt wurde, um die Behandlung zu vereinfachen und die Benutzererfahrung zu verbessern. Zwischen Januar und April 2024 wuchs die Anzahl neuer HHD-Patienten, die in den USA mit NxStage behandelt werden, im Vergleich zum selben Zeitraum im Jahr 2023 um 18%. Die 2023 von der FDA zugelassene Versi®HD mit GuideMe Software hat von verschiedenen Dialyseanbietern erhebliches Interesse geweckt. Ihre fortschrittliche Technologie zielt darauf ab, die Benutzerfreundlichkeit zu verbessern, die Schulungszeit zu verkürzen und verschiedene Lernstile zu berücksichtigen.
- Achieved milestone of over 14,000 U.S. patients using NxStage systems for Home Hemodialysis
- 18% growth in new HHD patients starting treatment with NxStage between January-April 2024 compared to 2023
- Launch of NxStage® Versi®HD with GuideMe Software, designed to simplify treatment and improve user experience
- Significant interest from large, mid-sized, and independent dialysis providers in adopting Versi®HD with GuideMe Software
- Reduced training time for patients using Versi®HD with GuideMe Software, with completion 7-10 days sooner
- None.
Insights
Fresenius Medical Care's milestone of 14,000 U.S. patients using NxStage systems for Home Hemodialysis (HHD) marks a significant advancement in home-based kidney care. The
The pictorial-based guidance system could be a game-changer, making HHD more accessible to a broader patient demographic. This innovation may lead to increased market share and revenue growth for Fresenius. However, investors should monitor the global rollout timeline and adoption rates among different-sized dialysis providers to gauge long-term success.
The growth in HHD patients using Fresenius' NxStage systems signifies a shift towards home-based care, aligning with broader healthcare trends. This could lead to cost savings for healthcare systems and improved quality of life for patients. The 927 new patients initiating HHD therapy in April alone suggests a robust growth trajectory.
The Versi®HD with GuideMe Software's focus on simplifying treatment and improving user experience addresses key barriers to HHD adoption. This could accelerate market penetration and potentially disrupt traditional in-center dialysis models. Investors should consider the long-term implications on Fresenius' clinic network and how this shift might impact the company's revenue mix and profitability in the coming years.
While specific financial figures are not provided, the growth in HHD patients and the launch of Versi®HD with GuideMe Software present positive indicators for Fresenius Medical Care's financial outlook. The
Investors should consider the potential impact on profit margins as the company transitions more patients to home-based care. The reduced need for in-center staffing and facilities could lead to cost savings, but this may be offset by increased R&D and manufacturing costs for home dialysis equipment. The global rollout of Versi®HD could drive international revenue growth, but the timeline and associated costs should be monitored closely.
- Fresenius Medical Care achieves growth milestone of more than 14,000
U.S. -based patients using the Company's NxStage systems to perform Home Hemodialysis therapy - This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapy
- The newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experience
Between January and April 2024, the number of new HHD patients starting treatment with NxStage in
"We are proud to announce these achievements in our Home Therapies division," said Joseph Turk, Executive Vice President and Global Head of Home Therapies at Fresenius Medical Care. "These accomplishments underscore our relentless commitment to continuous innovations that enable us to improve the lives of patients seeking the safety, convenience, and flexibility of home dialysis."
Since the FDA clearance in 2023, the newest NxStage HHD System, Versi®HD with GuideMe Software, has garnered significant interest in
Versi®HD with GuideMe Software's advanced technology is designed to simplify HHD treatment and improve ease of learning, skill retention, and user experience for patients and care partners. The machine's pictorial-based guidance was designed to meet diverse patient needs throughout the setup, treatment and troubleshooting, while improving training time and skill retention. It provides graphical walk-through guidance that aims to enhance ease of use and confidence for both patients and nurses. The interface is designed to accommodate a wide variety of learning styles and improve skill retention from initial training, while static picture instructions allow patients to linger and study any step at their own pace.
"The patient training on Versi®HD with GuideMe-Software at our clinic catch on quickly and feel comfortable by the second week of training. Even better, they are able to complete their training seven to 10 days sooner," said Sandra Flores, Home Therapies Registered Nurse in North Central Oklahoma City.
Currently, NxStage Versi®HD with GuideMe Software is being fully launched in the
© 2024 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, NxStage, and Versi are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,757 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 311,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Emanuela Cariolagian
T +1 213 706 0051
Emanuela.Cariolagian1@freseniusmedicalcare.com
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-grows-number-of-us-patients-using-companys-home-hemodialysis-machines-launches-nxstage-versihd-with-guideme-software-302237216.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
How many U.S. patients are using Fresenius Medical Care's NxStage systems for Home Hemodialysis?
What is the growth rate of new HHD patients starting treatment with NxStage in the U.S. for FMS in 2024?
What new home dialysis machine has Fresenius Medical Care (FMS) launched recently?
How does the NxStage® Versi®HD with GuideMe Software improve patient training for FMS?
